This is an appeal from the Registrar of Trademarks’ decision expunging the mark NAVIGATOR (registered for chemicals for use in the manufacture of paper products) pursuant to section 45 of the Trademarks Act. The additional evidence filed by the Applicant on appeal was found to be material and as such the Court proceeded on a de novo basis.

Alexion Pharmaceuticals Inc. brought an application, seeking to add Dr. Mark J. Evans as an inventor to Canadian Patent No. 2,645,810 [the “810 Patent”] and Canadian Patent No. 3,022,097 [the “097 Patent”]. The Court granted the application and added Dr. Evans as an inventor.

Takeda brought a motion to consolidate two actions commenced under the Patented Medicines (Notice of Compliance) Regulations, SOR/93-133. The parties agreed that if the actions were consolidated the trial dates would need to be postponed. The motion was dismissed.

In 2012, Puma Se (“Puma”) filed a trademark application for “procat” in association with certain clothing items related to footwear and headgear (the “Application”).

In this case, the Applicant (Cheung’s Bakery) successfully expunged two of the Respondent’s (Easywin) trademarks registrations.

On March 21, 2023, the Federal Court of Canada issued its decision in Dermaspark Products Inc v Patel, 2023 FC 388.

Services Juridiques Samuel Cohen (“SJSC”) brought a motion to remove themselves as solicitors of record. The motion was uncontested by the Plaintiff, who sought only to include terms in the Order that provide for a fixed time by which the Plaintiff could bring a motion to strike the Statement of Defence.

In this matter, the trial Judge provided a costs decision after finding patent infringement against the Defendant, Agracity.

In this decision, made by the second costs’ Assessment Officer assigned to the matter, the fact pattern is somewhat unusual. The Plaintiff, Georgetown Rail Equipment Company, had initially been successful at trial. The Federal Court found “the patents were not invalid on the ground of obviousness” and went on to find that “Tetra’s sale of the system to CN Rail and its support of the system infringed both patents.”

This is a motion by Janssen in a PMNOC s. 8 case (damages) for the drug abiraterone acetate (ZYTIGA) to obtain productions from third parties to this action, namely other generic pharmaceutical plaintiffs in other s. 8 cases.